Clinical trials: MDS/MPN
MDS, MDS/MPN
Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
PRO-RED is a prospective, longitudinal, and multicenter observational study. Enrolled patients will be followed for 6 months in at least monthly intervals in terms of their received red blood cell transfusions and routine…
- Trial name
- PRO-RED (NCT05582902)
- Where
- 11 sites in Austria, Germany
- Volunteers
- 60 people
- Sponsor
- University of Leipzig
Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia
Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
For the first 28 day cycle, all patients will be treated with single agent pacritinib at 200 mg twice daily. The investigators chose this starting dose based on the previous three phase I studies of pacritinib as a single agent…
- Conditions
- Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Myeloproliferative Neoplasm
- Trial name
- NCT02564536
- Testing
- Pacritinib, Decitabine
- Sponsor
- Washington University School of Medicine
Advanced Systemic Mastocytosis
Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies
The goal of this clinical trial is to evaluate elenestinib (BLU-263) in participants with Advanced Systemic Mastocytosis (AdvSM), SM with an associated hematologic neoplasm (SM-AHN), and other hematologic malignancies.
- Trial name
- AZURE (NCT05609942)
- Testing
- BLU-263, Azacitidine
- Where
- 11 sites in United States, Belgium and 5 more
- Volunteers
- 9 people
- Sponsor
- Blueprint Medicines Corporation
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced myeloid malignancies. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and spread…
- Trial name
- NCT01606579
- Testing
- PRI-724
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Prism Pharma Co., Ltd.
Myelodysplastic Syndromes (MDS)
The National Myelodysplastic Syndromes (MDS) Study
Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined…
- Trial name
- MDS (NCT02775383)
- Testing
- Therapeutic
- Where
- 281 sites in United States, Israel
- Volunteers
- 2,115 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myelodysplastic Syndromes, Myeloproliferative Neoplasms
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
This phase I/II trial studies how well Jaktinib and azacytidine work in treating patients with myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis.
- Conditions
- Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Myelofibrosis
- Trial name
- NCT04866056
- Testing
- Jaktinib, azacitidine
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia
Hematological Disorders in EHPVO Patients
This study focuses on patients who have a condition called extrahepatic portal vein obstruction (EHPVO), where a blood clot blocks the portal vein outside the liver.
- Conditions
- Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia, Myeloproliferative Neoplasms (MPN), Antiphospholipid Syndrome (APS)
- Trial name
- EHPVO-HEM (NCT07108023)
- Testing
- No intervention (Observational Study)
- Volunteers
- 115 people
- Sponsor
- Rahab Nady
MDS/MPN
Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN
This study observes the safety and efficacy of Azacitidine (AZA) combined with ruxolitinib to treat higher-risk Myelodysplastic Syndromes∕Myeloproliferative Neoplasms(MDS/MPN)
- Trial name
- NCT05817955
- Testing
- Azacitidine (AZA) with Ruxolitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
MDS/MPN
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation providing the framework for collaborative studies to advance treatment…
- Trial name
- ABNL-MARRO (NCT04061421)
- Testing
- ASTX727, Itacitinib, Ruxolitinib
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Michael Savona
Hematologic Malignancies, Inherited Disorders of Metabolism
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
- Conditions
- Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders
- Trial name
- NCT01351545
- Testing
- A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
- Where
- 142 sites in United States
- Volunteers
- 99,999 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
This phase II trial tests the safety, best dose, and effectiveness of ropeginterferon alfa-2b for the treatment of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and chronic myelomonocytic…
- Conditions
- Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified
- Trial name
- NCT07468916
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Acute Myeloid Leukemia, Myeloproliferative Neoplasm
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
This is a Phase 1, 2-part, open-label, multicenter, first-in-human (FIH) study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of TAS1553 administered orally to participants…
- Conditions
- Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT04637009
- Testing
- TAS1553
- Where
- 10 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Clonal Mast Cell Disease, KIT D816V Mutation
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
- Conditions
- Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
- Trial name
- POLARIS (NCT07143669)
- Testing
- Screening
- Where
- 26 sites in United States, Belgium
- Volunteers
- 750 people
- Sponsor
- Blueprint Medicines Corporation
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL)
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant.
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome)
- Trial name
- ACCELERATE (NCT06859424)
- Testing
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C
- Where
- 13 sites in United States
- Volunteers
- 358 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Leukemia, Myelomonocytic, Chronic
Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia
A Phase 2 study to investigate the antitumor activity in terms of overall response rate (ORR) of tipifarnib in approximately 36 eligible subjects with Myelodysplastic/Myeloproliferative Neoplasias (MDS/MPN), including Chronic…
- Trial name
- CMML/AML (NCT02807272)
- Testing
- Tipifarnib
- Where
- 8 sites in United States
- Volunteers
- 44 people
- Sponsor
- Kura Oncology, Inc.
Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
The purpose of the study is to see if participants with anemia due to their type of MDS or MDS/MPN will experience a more decreased need for regular blood transfusions if they take luspatercept plus best supportive care, and what…
- Conditions
- Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Anemia
- Trial name
- NCT05732961
- Testing
- Luspatercept
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Leukemia, MDS
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
A research investigation into the efficacy of digital Polymerase Chain Reaction (dPCR) for monitoring measurable residual disease (MRD) during allogeneic hematopoietic stem cell transplantation, with a focus on predicting relapse…
- Conditions
- Acute Leukemia, MDS, MDS/MPN, CML
- Trial name
- NCT06211166
- Testing
- Digital PCR, Quantitative PCR, MFC
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies.
- Conditions
- Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome
- Trial name
- NCT05665530
- Testing
- PRT2527, Zanubrutinib, Venetoclax
- Where
- 24 sites in United States, Australia and 8 more
- Volunteers
- 86 people
- Sponsor
- Prelude Therapeutics Incorporated
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
This is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation.
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MDS/MPN)
- Trial name
- NCT04639024
- Testing
- ADCT-301
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gwynn Long, M.D.
Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome)
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
The goal of this clinical trial is to evaluate the effectiveness and safety of the anti-NKG2A monoclonal antibody (Monalizumab) in patients undergoing haploidentical stem cell transplantation (Haplo-SCT) with post-transplantation…
- Conditions
- Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome), MPN (Myeloproliferative Neoplasms)
- Trial name
- NCT06892223
- Testing
- Monalizumab (anti-NKG2A monoclonal antibody)
- Where
- 2 sites in Italy
- Volunteers
- 42 people
- Sponsor
- Istituto Clinico Humanitas